Outcome of nonunion fractures in dogs treated with fixation, compression resistant matrix, and recombinant human bone morphogenetic protein-2

Anna M. Massie; Amy S. Kapatkin; Mark C. Fuller; Frank J. M. Verstraete; Boaz Arzi

doi:10.3415/VCOT-16-05-0082

Veterinary and Comparative Orthopaedics and Traumatology, Table of Contents

Vet Comp Orthop Traumatol 2017; 30(02): 153-159
DOI: 10.3415/VCOT-16-05-0082

Clinical Communication

Schattauer GmbH

Outcome of nonunion fractures in dogs treated with fixation, compression resistant matrix, and recombinant human bone morphogenetic protein-2

Anna M. Massie

¹University of California-Davis, Veterinary Medical Teaching Hospital, Davis, CA, USA

,

Amy S. Kapatkin

²University of California-Davis, Department of Surgical & Radiological Sciences, Davis, CA, USA

,

Mark C. Fuller

²University of California-Davis, Department of Surgical & Radiological Sciences, Davis, CA, USA

³Airdrie, Alberta, Canada

,

Frank J. M. Verstraete

²University of California-Davis, Department of Surgical & Radiological Sciences, Davis, CA, USA

,

Boaz Arzi

²University of California-Davis, Department of Surgical & Radiological Sciences, Davis, CA, USA

› Author Affiliations

Abstract

Summary

Objectives: To report the use of compression resistant matrix (CRM) infused with recombinant human bone morphogenetic protein (rhBMP-2) prospectively in the healing of non union long-bone fractures in dogs.

Methods: A longitudinal cohort of dogs that were presented with nonunion fractures were classified and treated with CRM soaked with rhBMP-2 and fracture fixation. They were followed with serial radiographs and evaluated for healing times and complications according to the time frame and definitions previously established for orthopaedic clinical cases.

Results: Eleven nonunion fractures in nine dogs were included. Median healing time was 10 weeks (range: 7–20 weeks). Major perioperative complications due to bandage morbidity were encountered in two of 11 limbs and resolved. All other complications were minor. They occurred perioperatively in eight of 11 limbs. Minor follow-up complications included short-term in one of two limbs, mid-term in one of three, and long-term in four of five limbs. Nine limbs returned to full function and two limbs returned to acceptable function at the last follow-up.

Clinical significance: Nonunion fractures given a poor prognosis via standard-of-care treatment were successfully repaired using CRM with rhBMP-2 accompanying fixation. These dogs, previously at high risk of failure, returned to full or acceptable function.

Keywords

Bone regeneration - bone morphogenetic protein 2 - BMP-2 - compression resistant matrix - nonunion

Full Text

References

References
1 Tzioupis C., Giannoudis PV.. Prevalence of long-bone non-unions. Injury 2007; 38 (Suppl. 02) S3-S9.
2 Marsh D.. Concepts of fracture union, delayed union, and nonunion. Clin Orthop Relat Res 1998; 355 (suppl) S22-30.
3 Sumner-Smith G.. Non-union fracture. In: Sumner-Smith G., Fackelman GE.. editors. Bone in Clinical Orthopedics. 2^nd edition Stuttgart, Germany: AO Publishing / Thieme; 2002: 349-358.
4 Sumner-Smith G.. Delayed unions and non-unions. Diagnosis, pathophysiology, and treatment. Vet Clin North Am Small Anim Pract 1991; 21: 745-760.
5 Risselada M., van Bree H., Kramer M.. et al. Evaluation of nonunion fractures in dogs by use of B-mode ultrasonography, power Doppler ultrasonography, radiography, and histologic examination. Am J Vet Res 2006; 67: 1354-1361.
6 Rosen V.. BMP2 signalling in bone development and repair. Cytokine Growth Factor Rev 2009; 20: 475-480.
7 Reddi AH., Huggins C.. Biochemical sequences in the transformation of normal fibroblasts in adolescent rats. Proc Natl Acad Sci 1972; 69: 1601-1605.
8 Reddi AH.. Cell biology and biochemistry of endochondral bone development. Coll Relat Res 1981; 1: 209-226.
9 Wozney JM., Rosen V., Celeste A.. et al. Novel regulators of bone formation: molecular clones and activities. Science 1988; 242: 1528-1534.
10 Herford AS., Lu M., Buxton AN.. et al. Recombinant human bone morphogentic protein 2 combined with an osteoconductive bulking agent for mandibular continuity defects in nonhuman primates. J Oral Maxillofac Surg 2012; 70: 703-716.
11 Bessa PC., Casal M., Reis RL.. Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts). J Tissue Eng Regen Med 2008; 2: 1-13.
12 Nakashima M., Reddi AH.. The application of bone morphogenetic proteins to dental tissue engineering. Nat Biotechnol 2003; 21: 1025-1032.
13 Reddi AH.. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotechnol 1998; 16: 247-252.
14 McKay WF., Peckham SM., Badura JM.. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE® Bone Graft). International Orthopaedics 2007; 31: 729-734.
15 King GN., Cochran DL.. Factors that modulate the effects of bone morphogenetic protein-induced periodontal regeneration: a critical review. J Periodontol 2002; 73: 925-936.
16 Pang EK., Im SU., Kim CS.. et al. Effect of recombinant human bone morphogenetic protein-4 dose on bone formation in a rat calvarial defect model. J Periodontol 2004; 75: 1364-1370.
17 Medtronic. 2.1 Infuse bone graft for certain oral maxillofacial and dental regenerative uses. Important medical information, 2010 [Document on internet] Available from: http://www.infusebonegraft.com/wcm/groups/mdtcom_sg/@mdt/@spinal/documents/documents/oral_maxillofacial_insert.pdf.
18 Lu SX., Fiorini T., Lee J.. et al. Evaluation of a compression resistant matrix for recombinant human bone morphogenetic protein-2. J Clin Periodontol 2013; 40: 688-697.
19 Helm G., Anderson DG., Andersson GB.. et al. Summary statement: bone morphogenetic proteins; basic science. Spine 2002; 29: S9
20 Seeherman HJ., Wozney J., Li R.. Bone morphogenetic protein delivery systems. Spine 2002; 27: S16-S23.
21 Schmoekel HG., Weber FE., Hurter K.. et al. Enhancement of bone healing using non-glycosylated rhBMP-2 released from a fibrin matrix in dogs and cats. J Small Anim Pract 2005; 46: 17-21.
22 Schmoekel HG., Weber FE., Seiler G.. et al. Treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein-2 delivered from a fibrin matrix. Vet Surg 2004; 33: 112-118.
23 Arzi B., Verstraete FJM., Huey DJ.. et al. Regenerating mandibular bone using rhBMP-2: Part 1 - Immediate reconstruction of segmental mandibulectomies. Vet Surg 2015; 44: 403-409.
24 Verstraete FJM., Arzi B., Huey DJ.. et al. Regenerating mandibular bone using rhBMP-2: Part 2- treatment of chronic, defect non-union fractures. Vet Surg 2015; 44: 410-416.
25 Spector DI., Keating JH., Boudrieau RJ.. Immediate mandibular reconstruction of a 5 cm defect using rhBMP-2 after partial mandibulectomy in a dog. Vet Surg 2007; 36: 752-759.
26 Arzi B., Cissell DD., Polard RE.. et al. Regenerative approach to bilateral rostral mandibular reconstruction in a case series of dogs. Front Vet Sci 2015; 2: 1-7.
27 Kirker-Head CA., Boudrieau RJ., Kraus KH.. Use of bone morphogenetic proteins for augmentation of bone regeneration. J Am Vet Med Assoc 2007; 231: 1039-1055.
28 Cook JL., Evans R., Conzemius MG.. et al. Proposed definitions and criteria for reporting time frame, outcome, and complications for clinical orthopaedic studies in veterinary medicine. Vet Surg 2010; 39: 905-908.
29 Faria MLE., Lu Y., Heaney K.. et al. Recombinant human bone morphogenetic protein-2 in absorbable collagen sponge enhances bone healing of tibial osteotomies in dogs. Vet Surg 2007; 36: 122-131.
30 Springer ING., Niehoff P., Acil Y.. et al. BMP-2 and bFGF in an irradiated bone model. J Craniomaxillofac Surg 2008; 36: 210-217.
31 Wurzler KK., DeWeese TL., Sebald W.. et al. Radiation-induced impairment of bone healing can be overcome by recombinant human bone morphogenetic protein-2. J Craniofac Surg 1998; 9: 131-137.
32 Palmer MP., Altman DT., Altman GT.. et al. Can we trust intraoperative culture results in nonunions?. J Orthop Trauma 2014; 28: 384-390.
33 Olszewski D., Streubel PN., Stucken C.. et al. Fate of patients with a “surprise” positive culture after nonunion surgery. J Orthop Trauma 2016; 30: e19-e23.
34 Zara JN., Siu RK., Zhnag X.. et al. High doses of bone morphogenetic protein 2 induces structurally abnormal bone and inflammation in vivo. Tissue Eng Part A 2011; 17: 1389-1399.
35 Smucker JD., Rhee JM., Singh K.. et al. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine (phila Pa 1976) 2006; 31: 2813-2819.
36 Vaidya R., Carp J., Sethi A.. et al. Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2. Eur Spine J 2007; 16: 1257-1265.
37 Cunningham NS., Paralkar V., Reddi AH.. Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression. Proc Natl Acad Sci 1992; 89: 11740-11744.
38 Friedlaender GE., Perry CR., Cole JD.. et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001; 83A (Suppl. 01) S151-S158.
39 Boyne PJ., Salina S., Nakamura A.. et al. Bone regeneration using rhBMP-2 induction in hemimandibulectomy type defects of elderly sub-human primates. Cell Tissue Bank 2006; 7: 1-10.